PureTech Health plc (PTCHF)

Market Cap	429.78M
Revenue (ttm)	468.00K
Net Income (ttm)	-82.47M
Shares Out	n/a
EPS (ttm)	-0.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161
Average Volume	2,685
Open	1.700
Previous Close	1.700
Day's Range	1.700 - 1.740
52-Week Range	1.660 - 3.000
Beta	0.95
RSI	38.51
Earnings Date	Apr 25, 2025

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 90
• Stock Exchange: OTCMKTS
• Ticker Symbol: PTCHF

Financial Performance

In 2023, PureTech Health's revenue was $3.33 million, a decrease of -78.68% compared to the previous year's $15.62 million. Losses were -$65.70 million, 30.5% more than in 2022.